We performed a randomised controlled trial of percutaneous tibial nerve stimulation (PTNS)
versus tolterodine for treating treatment naı¨ve women with overactive bladder (OAB).
Study design: 36 patients with symptoms of OAB were randomised to 3 months of treatment with
weekly PTNS or tolterodine (2 mg bid p.o.). The primary outcome measure was the difference of
micturitions per 24 h. The secondary outcome measure was the impact on quality of life (QoL) measured
with a visual analogue scale (VAS) between baseline and after 3 months of therapy.
Micturition frequencies did not decline significantly (p = 0.13) over time and there were no
significant treatment differences (p = 0.96). QoL was significantly dependent from its level at baseline
(p = 0.002) and showed improvement over time compared to baseline measurements but no significant
differences between both treatment groups (p = 0.07). Incontinence episodes per 24 h depended
significantly on the level at baseline (p = 0.0001) and declined significantly (p = 0.03) during 3 months of
therapy in both therapy groups. However no significant treatment differences on the reduction of
incontinence episodes in 24 h could be shown between both therapy groups (p = 0.89). PTNS had fewer
side effects than tolterodine (p = 0.04).
PTNS and tolterodine were both effective in reducing incontinence episodes and improving
QoL in patients with OAB but not micturition frequencies. PTNS had fewer side effects.